Retatrutide, a polyagonist, targets GLP-1, GIP, and glucagon receptors, showing additional metabolic benefits and body weight reduction in individuals with metabolic dysfunction-associated steatotic liver disease (MASLD). Here, GCG is linked to metabolic dysfunction-associated steatotic liver disease.